In vivo T-cell depletion and pharmacokinetic-based busulfan conditioning regimen improve the outcomes in acute myeloid leukemia (AML) in complete remission undergoing to allogeneic stem cell transplantation.
Roberto Bono, Cristina Rotolo, Giuseppe Sapienza, Corinne Spoto, Carmelo Costanza, Sergio Indelicato, Caterina Patti, Antonino Mulè, Valeria Calafiore, Giulia Arrigo, Alessandra Santoro, Laura Di Noto, Luca Castagna
原始摘要（英文原文）· Original abstract
Pharmacokinetic‐based busulfan administration improves the therapeutic window and in vivo T‐cell depletion with antilymphocyte globulins reduces graft‐versus‐host disease incidence. In this study, both were used, showing an improvement of clinical outcomes in patients with acute myeloid leukemia.
In vivo T-cell depletion and pharmacokinetic-based busulfan conditioning regimen improve the outcomes in acute myeloid leukemia (AML) in complete remission undergoing to allogeneic stem cell transplantation. — 科研速览 Science Skim